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The arterial wall is composed of three indepen­
dent layers (intima, media, and adventitia) that 
display a variety of physiological properties. 
The intima is a monolayer of interconnected 
endothelial cells attached to a thin extracellular 
matrix. The media, delimited by the hydro­
phobic internal and external elastic laminas, is 
the main structural component of the arterial 
wall and is mostly composed by vascular smooth 
muscle cells (VSMCs). A network of connec­
tive tissue, nerve endings, fibroblasts, and a few 
quiescent resident leukocytes compose the ad­
ventitia. The medial VSMCs help to maintain 
vascular integrity. Under physiological conditions, 
VSMCs are quiescent, contractile, and nonmigra­
tory, and display a differentiated phenotype. 
Pathological vascular wall remodeling involves 
structural and functional modifications that 
destabilize the ordered multilayered structure 
of the wall and change the mass of the tunica 
media (Heeneman et al., 2007). Remodeling 
occurs in response to various stimuli, including 
blood pressure changes, inflammatory responses, 
altered extracellular matrix composition, and 
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Artery wall remodeling, a major feature of diseases such as hypertension, restenosis, athero-
sclerosis, and aneurysm, involves changes in the tunica media mass that reduce or increase 
the vessel lumen. The identification of molecules involved in vessel remodeling could aid the 
development of improved treatments for these pathologies. Angiotensin II (AngII) is a key 
effector of aortic wall remodeling that contributes to aneurysm formation and restenosis 
through incompletely defined signaling pathways. We show that AngII induces vascular 
smooth muscle cell (VSMC) migration and vessel remodeling in mouse models of restenosis 
and aneurysm. These effects were prevented by pharmacological inhibition of calcineurin  
(CN) or lentiviral delivery of CN-inhibitory peptides. Whole-genome analysis revealed >1,500 
AngII-regulated genes in VSMCs, with just 11 of them requiring CN activation. Of these, the 
most sensitive to CN activation was regulator of CN 1 (Rcan1). Rcan1 was strongly  
activated by AngII in vitro and in vivo and was required for AngII-induced VSMC migration. 
Remarkably, Rcan1/ mice were resistant to AngII-induced aneurysm and restenosis.  
Our results indicate that aneurysm formation and restenosis share mechanistic elements  
and identify Rcan1 as a potential therapeutic target for prevention of aneurysm and  
restenosis progression.
© 2011 Esteban et al. This article is distributed under the terms of an Attribution– 
Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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can also be inhibited by overexpressing peptides that block 
the interaction of CN with the two docking sites present 
in the NFAT regulatory domain, one at the N­terminal 
(VIVIT peptide) and the other at the C­terminal (LxVP peptide; 
Aramburu et al., 1999; Liu et al., 1999; Martínez­Martínez 
et al., 2006). A family of endogenous CN modulators, called 
regulators of CN (RCANs; previously known as DSCR/
MCIP/calcipressin/Adapt78 in mammals), has recently been 
identified (Davies et al., 2007). RCAN1, identified through 
its association with Down syndrome (Fuentes et al., 1997), is 
implicated in several physiological and pathological processes, 
including tumor growth and angiogenesis, sepsis, cardiac 
hypertrophy, mast cell function, and synaptic plasticity and 
memory (Rothermel et al., 2001; Ryeom et al., 2003, 2008; 
Vega et al., 2003; Hoeffer et al., 2007; Baek et al., 2009; 
Minami et al., 2009; Yang et al., 2009).
To date, neither CN–NFAT signaling nor RCAN1 have 
been linked to AngII­elicited vessel remodeling. Although 
NFAT transcription factors are implicated in AngII signaling 
in VSMCs, published studies provide conflicting data on 
which NFATs mediate AngII signals in these cells (Suzuki 
et al., 2002; Yellaturu et al., 2002; Liu et al., 2005). Indeed, 
little is known about the signaling pathways regulating vas­
cular wall remodeling. In this paper, we show for the first 
time that CN and RCAN1 mediate AngII­induced VSMC 
migration, and, using mouse models of restenosis and aneurysm, 
demonstrate that AngII induces pathological artery wall re­
modeling via CN and RCAN1.
RESULTS
The CN–NFAT pathway is activated by AngII in vivo  
and mediates AngII-induced migration of VSMCs
To address the role of the CN–NFAT pathway in AngII­ 
induced signaling in VSMCs in vivo, we used minipump infu­
sion to treat mice with AngII and/or the CN inhibitor CsA. 
The presence of activated NFAT factors in the nuclei of cells 
of the aortic wall was then analyzed by in situ southwestern 
histochemistry on aortic sections. We found that AngII in­
duced sustained in vivo activation of NFAT factors in aortic 
VSMCs, endothelial cells, and adventitial cells (Fig. 1, A and B; 
and Fig. S1). NFAT staining was similar to that of SP1 
(Fig. 1 C), which is used as a control for nuclear staining 
pattern. NFAT activation was prevented by CsA and block­
ers of AngII type 1 receptor (AT1R) but not AngII type 2 
receptor (AT2R; Fig. 1 A).
To determine which NFAT family members mediate 
AngII signals in VSMCs, we analyzed their expression and 
dephosphorylation status (an index of activation). NFATc1, 
NFATc3, and NFATc4, but not NFATc2, were detected in 
untreated VSMCs and were readily dephosphorylated by 
AngII in a CsA­sensitive manner (Fig. 1 D).
We next investigated the potential role of CN in AngII­
induced VSMC migration. AngII increased VSMC motility in 
Transwell assays, and this was inhibited by pretreatment with 
CsA (Fig. 2, A and B). We previously showed that infection 
with lentivirus encoding GFP fused to LxVP or VIVIT peptides 
vessel injury. These stimuli activate resident medial VSMCs, 
among other cells, which contribute to vascular remodeling 
through numerous processes, including cell migration (Berk, 
2001). VSMC migration is critical for lesion development 
and progression in several vascular pathologies. VSMCs 
migrate toward specific chemoattractants released by mono­
cytes/macrophages, platelets, endothelial cells, or other VSMCs 
in the damaged vessel (Goetze et al., 1999).
Vascular remodeling is a central feature of diseases such 
as hypertension, restenosis, atherosclerosis, and aneurysm 
(Heeneman et al., 2007). For example, percutaneous balloon 
angioplasty, commonly used to treat ischemic heart disease 
and peripheral artery stenosis (obstruction), causes severe 
vascular wall remodeling, resulting in restenosis. Vascular 
wall remodeling is also observed in the aneurismal degenera­
tion of the abdominal aortic and iliac arteries (referred to as 
abdominal aortic aneurysm [AAA]; Heeneman et al., 2007; 
Forte et al., 2010). Intimal hyperplasia formation and re­
stenosis can be controlled by the use of drug­eluting stents 
(Iakovou et al., 2005) and pharmacological control of athero­
sclerotic risk factors can slow AAA growth in some cases 
(Chaikof et al., 2009). However, there is as yet no definitive 
treatment to prevent restenosis or the progression of small 
aneurysms. The identification of molecules involved in ves­
sel remodeling could therefore aid the development of treat­
ments for these pathologies.
Angiotensin II (AngII), the key product of the renin– 
angiotensin system, is one of the most important factors in­
fluencing vascular remodeling (Berk, 2001), contributing to 
altered vascular tone, VSMC dysfunction, and structural re­
modeling in response to vascular damage (Touyz, 2005). 
AngII induces VSMC migration (Greene et al., 2001) and 
contributes to aneurysm formation and restenosis in animal 
models and in humans (Daugherty et al., 2000; Heeneman 
et al., 2007; Weintraub, 2009). Two major AngII cell surface 
receptor subtypes have been cloned and characterized, AT1R 
and AT2R (Benigni et al., 2010). Both receptors play a role 
in regulating VSMC function but are thought to oppose each 
other (Benigni et al., 2010).
Despite the importance of AngII and VSMC migration 
and vascular remodeling, little is known about the signaling 
pathways that regulate these processes. One of the down­
stream effectors of AngII is the ubiquitously expressed serine/
threonine protein phosphatase CN (Crabtree and Olson, 
2002; Suzuki et al., 2002; Martínez­Martínez and Redondo, 
2004), whose primary and most thoroughly characterized 
substrates are members of the nuclear factor of activated 
T cells family (NFATc1, NFATc2, NFATc3, and NFATc4). 
Dephosphorylation of NFATs triggers their rapid transloca­
tion to the nucleus where they become transcriptionally 
active (Hogan et al., 2003). The CN–NFAT axis is implicated 
in several pathophysiological processes, including vascular 
and neural development, diabetes, and cardiac hypertrophy 
(Molkentin et al., 1998; Graef et al., 2001, 2003; Heit et al., 
2006). CN is inhibited by cyclosporin A (CsA; Liu et al., 
1991; Cardenas et al., 1995), and NFAT activation by CN 
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(I/M) ratio (Fig. 3 C) and a decrease in lumen area (Fig. 3 B). 
AngII­promoted inward growth was blocked by pretreatment 
with CsA, which also protected against basal injury–induced 
neointima formation, reducing the I/M ratio and the percent 
of stenosis almost to basal (noninjured) levels (Fig. 3).
Extensive remodeling of the artery wall is a hallmark of 
aneurysm formation and progression (Heeneman et al., 2007), 
a process promoted by AngII in animal models and humans 
(Weintraub, 2009). To investigate the mechanisms under­
lying AngII­induced aneurysm, we used the apolipoprotein 
E–deficient (Apoe/) mouse model. As previously described 
(Daugherty et al., 2000; Daugherty and Cassis, 2004), AngII 
promoted the formation of AAA in Apoe/ mice (Fig. 4). 
This effect was strongly reduced by pretreatment with CsA 
(Fig. 4); whereas 79% of Apoe/ mice treated with AngII 
alone developed AAA, only 11% of mice pretreated with 
prevents NFAT activation (Martínez­Martínez et al., 2006; 
Rodríguez et al., 2009). Expression of GFP­LxVP or GFP­
VIVIT in VSMCs (Fig. S2 A) abolished the VSMC migra­
tory response to AngII (Fig. 2 C and Fig. S2 B). In contrast, 
GFP­LxVPmut, encoding a mutated LxVP peptide, had no 
effect (Fig. 2 C and Fig. S2 B).
CN is implicated in AngII-induced arterial damage
To assess the involvement of AngII signaling in pathological 
vascular remodeling, we first used a mouse model in which 
femoral artery injury is induced by passage of an angioplasty 
guidewire, mimicking the damage caused by angioplasty in 
humans (Roque et al., 2000). Guidewire injury promoted 
neointima formation (Fig. 3). AngII infusion increased this inti­
mal thickening without disrupting elastic integrity (Fig. 3 A), 
which was reflected in a sharply increased intima/media 
Figure 1. AngII activates the CN–NFAT pathway in VSMCs in vivo. (A–C) Mice were inoculated with 5 mg/kg/d CsA, 10 mg/kg/d of the AngII type 1 
receptor (AT1) blocker losartan, or 30 mg/kg/d of the AngII type 2 receptor (AT2) blocker PD123319 by subcutaneous osmotic minipump infusion for 24 h 
before similar administration of 1 µg/kg/min AngII for 1 h. Aortic sections from these mice were analyzed by Southwestern histochemistry with NFAT 
probe (A), hematoxylin-eosin (HE) staining (B), and Sp1 immunohistochemistry (C). Bars, 50 µm. (D) NFAT immunoblot in extracts from VSMCs stimulated 
with 1 µM AngII for 1 h after pretreatment as indicated (1 h) with 200 ng/ml CsA. Arrowheads indicate NFAT proteins with different degrees of phos-
phorylation. NFATc2 was tested in parallel protein extracts of Jurkat cells (JK). Representative experiments are shown of four to six performed.
Figure 2. CN mediates AngII-induced 
VSMC migration. (A and B) VSMCs were 
seeded on the upper surface of the polycar-
bonate membranes of chemotaxis (Transwell) 
chambers containing no stimulus, 1 µM AngII, 
or 1 µM AngII plus 200 ng/ml CsA in the 
lower chamber. After 4 h, nonmigrating cells 
were removed from the upper filter surfaces 
and the filter was stained with Hoechst.  
(A) Representative images of the lower filter 
surface. Bar, 50 µm. (B) Quantification of 
migrated VSMCs in 10 fields per condition in 
a representative transwell experiment of six to 
seven performed (means ± SEM). (C) VSMCs 
infected with lentiviruses expressing GFP-tagged LxVP, LxVPmutant, or VIVIT peptides and treated as indicated in A and B. Quantification is shown of  
migrated VSMCs in 10 fields per condition in a representative transwell experiment of six to seven performed (means ± SEM).
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establishing a clear correlation between activation of 
the CN–NFAT pathway by AngII and subsequent arterial 
damage (Fig. 5 C).
Rcan1-4 is required for AngII-induced migration of VSMCs
To investigate the mechanism by which CN mediates AngII­
induced vascular damage, we screened mouse aortic VSMCs 
for expression of AngII­regulated genes sensitive to CsA. Analy­
sis of mouse whole­genome arrays with gene expression dy­
namics inspector (Eichler et al., 2003) revealed that AngII 
altered the expression of many genes in mouse aortic VSMCs, 
whereas CsA barely affected gene expression and did not 
grossly alter the transcriptome of AngII­treated cells (unpub­
lished data). Just 11 of >1,500 AngII­regulated genes were 
significantly affected by CsA treatment (Fig. 6 A), arguing 
strongly for a specific action of CN signaling in the AngII 
response. Of these genes, only Rcan1 was inhibited by >70% 
and was thus identified as a candidate mediator of AngII 
signaling in VSMCs.
CsA developed the condition. CsA prevented AngII­induced 
changes in overall abdominal aorta morphology (Fig. 4 A), 
blocked the increase in aorta diameter (Fig. 4, B and C) and 
collagen deposition (Fig. 4 D), and prevented destabilization 
of the ordered multilayered artery wall structure (Fig. 4 D). 
Treatment with CsA alone did not significantly modify over­
all aorta morphology or maximal diameter (Fig. 4, A–C). Re­
markably, numerous adventitial cells were positive for smooth 
muscle ­actin (SMA) in aneurysm sections from AngII­ 
infused mice (Fig. 4 E).
To confirm the involvement of CN in AngII­induced 
AAA, we inoculated Apoe/ mice with lentivirus encod­
ing LxVP or LxVPmutant before AngII infusion. This sys­
temic administration yielded efficient transduction of VSMCs 
in vivo (Fig. 5 A). LxVP, but not LxVPmutant, completely 
prevented AngII­induced AAA (Fig. 5 B). Active NFAT was 
abundant in aneurysm sections of AngII­treated mice 
but was not detected in sections from CsA­pretreated mice 
or from animals infected with LxVP lentiviruses, thus 
Figure 3. CsA inhibits AngII-induced neointimal formation in a model of femoral artery injury. The left femoral artery was wire injured and 
AngII was administrated by subcutaneous minipump infusion during 14 d. CsA administration commenced 24 h before treatment with AngII and contin-
ued throughout the AngII infusion period. (A) Representative images of left femoral artery cross sections stained with hematoxylin-eosin (HE), Van Gieson (VG), 
and Masson’s trichrome (Masson). Bar, 50 µm. (B) Summary of morphometric data of the different treatment groups. Area data are shown in micrometers 
squared. Because the endothelial monolayer appeared as a line in the noninjured arteries, its area was considered to be 0, and the mean I/M ratio and 
percentage of stenosis were also 0. (C) Quantification of the ratio of the thickness of intima and media (I/M ratio) in the injured conditions shown in A. 
Data are means ± SEM. Numbers of mice per group were 7 saline, 13 AngII, 7 CsA+AngII, 5 CsA, and 10 noninjured. *, P < 0.05 versus control;  
#, P < 0.05 versus AngII. Results in A–C were pooled data from two independent experiments.
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activation of the Rcan1 promoter. 
A combination of a phorbol ester and 
calcium ionophore (PIo), used as a 
positive control (Cano et al., 2005), 
activated the wild­type promoter as much as AngII (Fig. 6 F). 
Similar results were obtained with rat aortic VSMCs (Fig. S3 B). 
These results indicate that AngII induces Rcan1-4 mRNA 
expression via CN–NFAT activation.
To investigate whether Rcan1 plays a role in AngII­ 
induced VSMC migration, we examined the effect of AngII 
on aortic VSMCs derived from Rcan1-deficient mice (Porta 
et al., 2007). Western blotting confirmed the absence of 
Rcan1­1 and Rcan1­4 proteins in aortic tissue sections from 
Rcan1/ mice, whereas expression of both proteins was 
detected in AngII­stimulated Rcan1+/+ mice (Fig. S4 A). Rcan1 
loss of function had no significant effect on NFATc4 phos­
phorylation status or subcellular localization, either in unstimu­
lated VSMCs or cells activated with AngII or calcium ionophore 
(Fig. S4, B and C). Consistently, aortic tissue and VSMC 
extracts from Rcan1+/+ and Rcan1/ mice showed similar 
levels of CN activity toward the specific substrate RII phos­
phopeptide (Fig. S4 D). Moreover, the pattern of NFAT 
in vivo activation by AngII was similar in aortic tissues from 
Rcan1+/+ and Rcan1/ mice (Fig. S4 E). Together, these 
results strongly suggest that Rcan1 deficiency does not signifi­
cantly affect CN activity in VSMCs. Rcan1/ VSMCs did not 
migrate in response to AngII in Transwell assays, whereas 
VSMCs of both genotypes responded similarly to fetal calf 
Rcan1 is expressed as two isoforms, Rcan1-1 and Rcan1-4 
(Genescà et al., 2003). Real­time quantitative PCR (qPCR) 
detected induced Rcan1-4 mRNA expression 1 and 4 h after 
stimulation of VSMCs with AngII, and this was reduced 
almost to basal levels by pretreatment with CsA (Fig. 6 B). 
Similar results were obtained with rat aortic VSMCs (Fig. S3 A), 
demonstrating that regulation of Rcan1-4 expression by 
AngII is not exclusive to mouse cells. Rcan1­4 was barely 
detected in unstimulated mouse VSMCs but was strongly in­
duced by AngII in a CsA­sensitive manner (Fig. 6 C). AT1R 
antagonist, but not AT2R antagonist, abolished induced ex­
pression of Rcan1­4 (Fig. 6 D). AngII­induced Rcan1­4 
protein expression was also inhibited by infection with 
lentivirus encoding LxVP or VIVIT but not LxVPmutant 
(Fig. 6 E). Rcan1­1 was constitutively expressed (Fig. 6 C).
We next transfected mouse VSMCs with luciferase 
reporter vectors driven by an internal Rcan1 promoter 
(RCAN(350/+83)) or a derived sequence in which the 
NFAT interacting motif is mutated (RCAN(350/
+83)mut; Minami et al., 2004). AngII­induced activation 
of the RCAN(350/+83) reporter was strongly inhibited 
by CsA (Fig. 6 F). The RCAN(350/+83)mut reporter 
was barely affected by AngII stimulation (Fig. 6 F), suggesting 
that NFAT factor binding is required for AngII­mediated 
Figure 4. CsA inhibits development of 
AngII-induced AAA. Apoe/ mice were 
minipump infused with 5 mg/kg/d CsA, 1 d 
before commencing similar administration 
with saline or 1 µg/kg/min AngII for 28 d.  
(A) Representative abdominal aortas of 
Apoe/ mice treated as indicated. (B) Repre-
sentative high-frequency ultrasound (US) 
images of abdominal aortas. Transverse (top) 
and longitudinal (bottom) images were taken 
at the level of the suprarenal aorta. Yellow 
lines mark the lumen boundary. (C) Maximum 
suprarenal abdominal aortic diameter (in mil-
limeters) measured from transverse US  
images. Triangles and squares represent  
individual mice and means ± SEM, respectively.  
Numbers of mice per group were 9  
saline, 24 AngII, 9 CsA+AngII, and 7 CsA.  
*, P < 0.05 versus AngII. (D) Representative 
Masson’s trichrome staining of suprarenal 
abdominal aorta cross sections. Bars: 200 µm 
(top); 50 µm (bottom). (E) Representative 
immunohistochemical staining for SMA in 
suprarenal abdominal aorta cross sections 
from saline and AngII-treated mice. Bars:  
100 µm (top); 50 µm (bottom and insets I and II). 
(A–E) Numbers of mice per group were 9 sa-
line, 24 AngII, 9 CsA+AngII, and 7 CsA. Results 
were pooled from two independent experi-
ments and are representative of four.
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Rcan1 was detected in the tunica media of aortic sections 
from control­treated Apoe/ mice, and its expression was 
notably increased in medial and adventitial cells of AAA sec­
tions from AngII­infused mice (Fig. 9 A and Fig. S7 A). 
Western blotting revealed a sharp increase in Rcan1­4 ex­
pression in this tissue (Fig. 9 A). Both medial and adventitial 
cells from AAA also expressed SMA, which was restricted to 
the tunica media in control tissues (Fig. 9 B and Fig. S7 A). 
Vimentin­positive cells were also found in the adventitia of 
control aortae and AAA, whereas CD3­ and Mac3­positive 
cells were found in the adventitia of aneurysmal sections but 
not in control aortae (Fig. 9 B and not depicted).
To investigate the involvement of Rcan1 in AAA for­
mation, we established Apoe/Rcan1/ double­knockout 
mice and analyzed their response to AngII. In contrast to 
Apoe/Rcan1+/+ mice, abdominal aortae and tissue sections from 
AngII­stimulated double­knockout mice (Apoe/Rcan1/) 
were almost indistinguishable from samples from saline­ 
infused mice (Figs. 9, C–E). No significant wall remodeling 
was observed in abdominal aorta tissue sections from AngII­
treated Apoe/Rcan1/ mice (Fig. 9 E). These findings were 
reflected in a significantly lower maximal aortic diameter in 
Apoe/Rcan1/ mice compared with Apoe/Rcan1+/+ mice 
(Fig. 9 F). Remarkably, whereas 82% of AngII­infused Apoe/ 
Rcan1+/+ mice developed AAA, no Apoe/Rcan1/ mice 
developed this condition.
serum, confirming that AngII­induced VSMC migration spe­
cifically requires Rcan1 (Figs. 7, A and B). Supporting these 
findings, AngII­stimulated Rcan1+/+ VSMCs efficiently reoccu­
pied the denuded area in wound healing assays, whereas simi­
larly treated Rcan1/ VSMCs did not (Fig. 7 C). The migratory 
response to AngII was rescued by adenoviral­mediated re­
expression of Rcan1­4 in Rcan1/ VSMCs (Fig. 7 D  
and Fig. S5).
Rcan1 mediates AngII-induced vascular damage
We next analyzed the potential role of Rcan1 in the mouse 
models of AngII­induced restenosis and aneurysm. Rcan1 
was detected in femoral artery sections after guidewire injury 
in AngII­treated mice (Fig. 8 A). Rcan1 expression was 
detected in the tunica media (Fig. 8 A) but, in some cases, 
could also be detected in neointimal cells (Fig. S6). The arteries 
of Rcan1/ mice were completely protected against the 
AngII­induced increase in intima thickness (Figs. 8, B and C), 
reflected in a near­basal level of stenosis (2.62 ± 2.5%). AngII 
thus appears to exacerbate neointima formation during 
vascular injury through the activation of CN and the induc­
tion of Rcan1­4 expression. Because T cells are also critical 
for neointima formation (Maiellaro and Taylor, 2007), we 
assessed their presence in femoral artery sections. T cells were 
found in the adventitia of injured vessels distributed in a ring­
like fashion around the external elastic (Fig. S6).
Figure 5. Systemic delivery of LxVP 
lentivirus inhibits development of AngII-
induced AAA. (A) Mice were inoculated with 
lentivirus expressing GFP-tagged LxVP or 
LxVPmutant 100 µl virus solution (1011 par-
ticles in 100 µl) injected directly into the right 
jugular vein 1 mo before staining of aortic 
sections. (A) GFP immunostaining in aortic 
sections. IgG staining serves as a negative 
control. Bars: 100 µm (left); 50 µm (middle 
and right). A representative experiment is 
shown of six performed in independent 
mice. (B) Apoe/ mice were inoculated with 
lentivirus expressing GFP-tagged LxVP or 
LxVPmutant 1 mo before minipump- 
infusion of 1 µg/kg/min AngII for 28 d. Maxi-
mum suprarenal abdominal aortic diameter 
(in millimeters) is shown. Triangles and 
squares represent individual mice and means 
± SEM from six mice per condition, respec-
tively. *, P < 0.05 versus LxvPmut. (C) Apoe/ 
mice were inoculated (bottom) or not (top) 
with lentivirus expressing GFP-tagged LxVP or 
LxVPmutant 1 mo before minipump infusion 
with 5 mg/kg/d CsA 1 d before commenc-
ing similar administration with saline or  
1 µg/kg/min AngII for 14 d. Aortic sections from 
these mice were analyzed by Southwestern 
histochemistry with NFAT probe. Bars, 50 µm. 
Representative images are shown of six mice 
per group. Results in A–C are representative 
of two independent experiments.
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vascular diseases (Casscells, 1992; Schwartz, 1995, 1997; Curci, 
2009), and activates Rcan1­4 expression in neointima growth 
and aneurysm. We propose that CN–NFAT­activated in­
duction of Rcan1­4 expression by AngII mediates migration 
of VSMCs during vascular remodeling, and we hypothesize 
that this migration might be essential for the onset of related 
pathologies such as neointima formation and AAA.
The growth­promoting effects of AngII on VSMCs are 
thought to contribute to the pathogenesis of various cardio­
vascular diseases. However, the evidence for growth­ 
promoting effects of AngII on VSMCs is conflicting. Thus, 
although many groups have reported increased DNA syn­
thesis in VSMCs treated with AngII (Watanabe et al., 2001; 
Sayeski and Ali, 2003; Nagata et al., 2004; Guo et al., 2009), 
some of these results showed that AngII did not increase 
cell number (Watanabe et al., 2001). Other groups even re­
ported that AngII was not mitogenic in VSMCs (Geisterfer 
et al., 1988; Berk et al., 1989; Owens, 1989). Although our 
data show that AngII is a strong inducer of VSMC migra­
tion, we also found that it is only a very modest activator of 
VSMC proliferation (unpublished data), which is consistent 
with previous studies (Watanabe et al., 2001; Guo et al., 
2009). However, because Angll induces the synthesis of 
potent mitogens such as PDGF (Naftilan et al., 1989) or ET­1 
(Emori et al., 1989; Scott­Burden et al., 1991), it might 
Because Rcan1 was found in the adventitia and this layer 
contained hematopoietic cells, we investigated whether Rcan1 
expression in these cells was critical for AngII­induced AAA. 
To this end, we transplanted Apoe/Rcan1/ or Apoe/ 
Rcan1+/+ bone marrow cells into irradiated Apoe/Rcan1+/+ 
mice. After verification of successful engraftment 2 mo after 
transplantation (Fig. S7 B), we treated the mice with AngII 
for 28 d. We found no gross differences in AAA formation 
between the two groups of transplanted mice (Fig. 9 G), sug­
gesting that Rcan1 expression in leukocytes is not essential 
for AngII­induced aneurysm.
DISCUSSION
Our results provide evidence that CN–NFAT­mediated in­
duction of Rcan1­4 plays a central role in AngII­induced 
artery obstruction and aortic aneurysm formation. Comple­
mentary approaches demonstrate that CN is required for 
AngII­induced Rcan1­4 expression, that Rcan1­4 is a key 
mediator of AngII­induced VSMC migration, and that CN 
and Rcan1 are both required for AngII­induced vessel re­
modeling in restenosis and aneurysm.
Although the mechanisms of AngII­induced remodeling 
in AAA and restenosis are different, our findings identify 
a common link. AngII promotes VSMC migration, a critical 
event for lesion development and progression in several 
Figure 6. AngII induces CN-dependent gene 
and protein expression of Rcan1 in VSMCs.  
(A–D) VSMCs were stimulated with 1 µM AngII after 
pretreatment for 1 h with 200 ng/ml CsA, 1 µM of 
the AT1 blocker ZD7155, or 10 µM of the AT2 blocker 
PD123319. (A) RNA expression in VSMCs stimulated 
with AngII for 4 h after pretreatment or not with CsA 
was analyzed by hybridization of arrays. Expression of 
the indicated genes in the array under each experi-
mental condition is shown as fold changes (log2) 
relative to control cells (P < 0.05 vs. control).  
(B) qPCR analysis of Rcan1 mRNA expression after 
AngII treatment for 1 and 4 h. mRNA amounts were 
normalized to Tbp expression and data are expressed 
as the fold change relative to nonstimulated cells. 
Means of triplicate qPCR determinations for each 
condition are shown from a representative experi-
ment of five performed. (C) Time course Rcan1  
immunoblot in VSMCs treated as indicated.  
(D) Immunoblots showing the effect of AT1 or AT2 
blockers on AngII-stimulated Rcan1-4 expression. 
PIo, cells stimulated with a phorbol ester plus calcium 
ionophore A23187. (E) Immunoblots showing Rcan1-4  
expression in VSMCs infected with lentiviruses ex-
pressing GFP-tagged LxVP or LxVPmutant peptides 
and treated as indicated. (C–E) Tubulin expression 
was used as loading control. Representative experi-
ments of four to six performed are shown. (F) Rela-
tive luciferase activity from VSMCs transfected with 
the indicated reporters and treated as indicated 
above. PIo treatment was used as a positive control. 
Values are means ± SEM of triplicate luciferase deter-
minations for each condition from five experiments.
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cellular components and its size have been reported in animal 
models of restenosis (Maiellaro and Taylor, 2007). In addi­
tion, the pathogenesis of AAA has been shown to initiate with 
macrophage recruitment into the adventitia (Gavrila et al., 
2005), which is followed by additional lymphocyte and macro­
phage infiltration during its development (Daugherty et al., 
2000). Adventitial fibroblasts become activated during vessel 
remodeling and stay in the adventitia as nonmigratory, but 
indirectly potentiate VSMC proliferation in vivo. Whether 
Rcan1 participates in AngII­induced VSMC growth re­
mains to be determined.
Medial VSMCs are not the only cells participating in 
AngII­induced vascular remodeling. Endothelial cells from 
the intima layer and adventitial cells also play essential roles 
during pathological remodeling. The adventitia, in particular, 
has recently received considerable attention. Changes in its 
Figure 7. Rcan1 is required for AngII-induced VSMC migration. (A and B) Rcan1+/+ and Rcan1/ VSMCs were seeded on the upper surface of 
chemotaxis (Transwell) chambers containing no stimulus, 1 µM AngII, 1 µM AngII plus 200 ng/ml CsA, or 10% FBS (Serum) in the lower chamber. After 4 h,  
nonmigrating cells were removed from the upper filter surfaces and the filter was stained with Hoechst. (A) Representative images of the lower filter 
surface. Bar, 50 µm. (B) Quantification of migrated VSMCs in 10 fields per condition in a representative transwell experiment of six to seven performed 
(means ± SEM). (C) Representative images of a wound-healing assay of four performed with Rcan1+/+ and Rcan1/ VSMCs treated as indicated. Lines 
mark the wound limits after 4 h. Bar, 100 µm. (D) Quantification of migrated Rcan1/ VSMCs infected with Ad-GFP or Ad-Rcan1-4 and treated as indi-
cated. Cells were counted in 10 fields per condition. Data are means ± SEM of three independent experiments. *, P < 0.05 versus control.
Figure 8. Rcan1 mediates AngII-induced neointima formation. The left femoral artery was wire injured and AngII was administrated by subcutane-
ous minipump infusion during 14 d. CsA administration commenced 24 h before treatment with AngII and continued throughout the AngII infusion  
period. (A) Representative Rcan1 immunostaining of left femoral artery cross sections from AngII-treated Rcan1+/+ and Rcan1/ mice (n = 5/group).  
Bar, 50 µm. (B) Images of femoral artery cross sections from AngII-treated Rcan1+/+ and Rcan1/ mice stained with hematoxylin-eosin (HE), Van Gieson 
(VG), and Masson’s trichrome stains. Bar, 50 µm. Representative experiments are shown of 8–11 performed. (C) Quantification of the I/M ratio between 
groups. Data are means ± SEM. Mice per group were 8 Rcan1+/+AngII and 11 Rcan1/AngII. *, P < 0.05 versus Rcan1+/+AngII. Results in A and B are rep-
resentative of two independent experiments. Pooled data from two independent experiments are shown in C.
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deletion of Rcan1 
in hematopoietic 
cells does not pre­
vent AngII­induced 
AAA, Rcan1 expression in these cells does not seem to be critical 
for AAA formation. Given that AngII­elicited VSMC migration 
requires Rcan1 expression and that VSMC migration is central 
to vessel remodeling, we propose that Rcan1 expression in 
VSMCs or myofibroblasts is critical for vascular remodeling 
in vasculopathies. However, we do not exclude that its ex­
pression in endothelial cells or proliferating fibroblasts 
might also contribute to this remodeling.
RCAN1 was originally identified as a negative regulator 
of CN activity (Rothermel et al., 2000; Davies et al., 2007), 
but other studies suggest that it might not always have this 
effect (Kingsbury and Cunningham, 2000; Vega et al., 2003). 
It may be that regulation of CN activity by Rcan1 de­
pends on cell type, tissue, or stimulus, or that Rcan1 inhibits 
CN only at specific developmental or disease stages. In this 
regard, phosphorylation of Rcan1 converts it from inhibitor 
proliferating, fibroblasts, or are phenotypically converted into 
smooth muscle–like cells named myofibroblasts (Sartore et al., 
2001). Of note, both myofibroblasts and activated VSMCs ex­
press SMA and SM22 (Sartore et al., 2001). Conversely, medial 
VSMCs, when activated in the course of vascular remodeling, 
display structural and functional features common to imma­
ture, developmentally related cells that are hardly distinguish­
able from myofibroblasts (Owens, 1995; Sartore et al., 1999).
We detected activated NFAT and Rcan1 expression in 
VSMCs, endothelium, and adventitial cells. In the adventitia 
of AAA sections, CD3­ and Mac3­positive cells were readily 
detected, indicating the presence of T lymphocytes and 
macrophages. In addition, other adventitial cells were positive 
for vimentin or SMA expression, suggesting the presence of 
fibroblasts, myofibroblasts, or activated VSMCs. We also found 
numerous cells double positive for SMA and Rcan1 in media 
and adventitia of AAA sections, but it is likely that Rcan1 is 
also expressed in infiltrating leukocytes and vimentin­positive 
cells. Rcan1 expression in any of these cells could potentially 
be critical for pathological vessel remodeling. However, because 
Figure 9. Rcan1 mediates AngII-induced 
AAA. Apoe/Rcan1+/+ or Apoe/Rcan1/ 
mice were minipump infused with 1 µg/kg/
min AngII for 28 d. (A) Rcan1 immunostaining 
(top) of abdominal aortic cross sections from 
saline- and AngII-treated Apoe/Rcan1+/+ 
mice. IgG-staining serves as negative control. 
Rcan1-4 immunoblot of thoracic aorta (t)  
and the AAA segment of Apoe/Rcan1+/+ mice 
are shown. Bar, 50 µm. (B) CD3, Mac3,  
SMA, and vimentin immunostaining of abdominal 
aortic cross sections from AngII-treated 
Apoe/Rcan1+/+ mice. Bar, 50 µm. (A and B) Rep-
resentative experiments are shown of four 
performed. (C) Abdominal aortas from AngII-
treated mice. (D) Ultrasound images of ab-
dominal aortas from AngII-infused animals. 
Transverse (top) and longitudinal (bottom) 
images were taken at the level of the supra-
renal aorta. Yellow lines mark lumen boundary. 
(E) Suprarenal abdominal aorta cross sections 
stained with Masson’s trichrome. Bar, 100 µm. 
(C–E) Representative experiments are shown 
of 15–16 performed. (F and G) Maximum 
suprarenal abdominal aortic diameter (in mil-
limeters) in AngII-treated mice measured at 
treatment start and treatment finish. (F) Tri-
angles and squares represent individual mice 
and means ± SEM from Apoe/Rcan1+/+ 
mice (n = 16) and Apoe/Rcan1/ mice  
(n = 15), respectively. *, P < 0.05 versus Apoe/ 
Rcan1+/+. (G) Diamonds represent individual 
Apoe/Rcan1+/+ mice transplanted with 
bone marrow–derived cells from Apoe/ 
Rcan1+/+ mice (Rcan1+/+; n = 6) and Apoe/ 
Rcan1/ mice (Rcan1/; n = 6). Red 
crosses (†) indicate mice that died before 
completion of the experiment and showed a 
ruptured aneurysm. Results shown in C–E are 
representative of three performed. Pooled 
data from two independent experiments are 
shown in F. A representative experiment of 
two is shown in G.
2134 Rcan1 in vascular wall diseases | Esteban et al.
AngII elicits the formation of inositol­triphosphate (IP3), 
which leads to Ca2+ accumulation in the cytosol and CN 
activation. Activation of these multiple pathways regulates the 
expression of numerous genes. Indeed, we have found that a 
very large number of genes is regulated by AngII in VSMCs 
(unpublished data). Remarkably, only 11 of these genes were 
sensitive to CsA and therefore regulated by CN. Moreover, 
only one of these genes, Rcan1, was inhibited by CsA by 
>70%. The RT­PCR and other in vitro data confirm that 
this inhibition relates to the isoform Rcan1-4. Using pharma­
cological inhibitors of CN and lentiviral delivery of CN­ 
inhibitory peptides, we show that, among the numerous 
signaling cascades triggered by AngII, that mediated by IP3­
Ca2+­CN is critical for Rcan1­4 induction and VSMC 
migration. Moreover, Rcan1­deficient mice, including newly 
generated Apoe/Rcan1/ double knockouts, were protected 
against AngII­induced vessel remodeling. These results 
strongly argue for a specific action of CN–NFAT/Rcan1­4 
signaling in the AngII response and provide strong evidence 
that, despite the clear differences between restenosis and an­
eurysm, CN–NFAT­induced Rcan1­4 expression is central 
to the mechanism of AngII­induced vascular damage and in­
dicate that restenosis and AAA share mechanistic features.
Our findings might provide the basis for nonsurgical ther­
apies to prevent restenosis and inhibit aneurysm growth. 
Although the introduction of drug­eluting stents has im­
proved the prevention and treatment of restenosis (Iakovou 
et al., 2005), an 8–17% neointimal obstruction persists in most 
cases (Waseda et al., 2009). Moreover, the entrapped immuno­
suppressive and cytostatic agents are relatively nonspecific 
(Marx and Marks, 2001; Bhatia et al., 2004) and are associated 
with late­stent thrombosis (Iakovou et al., 2005). Regarding 
human AAA, surgical repair is considered appropriate for large 
aneurysms, but the overall 30­d mortality is 5% (Sakalihasan 
et al., 2005). Although pharmacological control of blood pres­
sure, diabetes, hyperlipidemia, and other atherosclerotic risk 
factors can slow AAA growth in some cases (Chaikof et al., 
2009), there is as yet no definitive treatment to prevent the 
progression of small aneurysms. More efficient therapies are 
therefore required for both pathologies.
Although pharmacological inhibition of CN with CsA 
prevents AngII­induced neointima formation and aneurysm 
development in our mouse models, its therapeutic use in 
humans for related diseases would require careful evaluation 
because of its severe side effects, which include neurotox­
icity, diabetes, nephrotoxicity, and hypertension. CsA disrupts 
CN phosphatase activity and thus affects all downstream sig­
nal transduction pathways. This broad action might explain 
some of its undesired side effects and toxicity. Moreover, CsA 
toxicity is at least partly independent of CN (Kiani et al., 
2000; Martínez­Martínez and Redondo, 2004). A more spe­
cific inhibition of the CN–NFAT pathway can potentially be 
achieved with CN­interacting peptides, but although these 
peptides are more selective than CsA, they also inhibit CN 
phosphatase activity or block its interaction with other substrates 
(Aramburu et al., 1999; Martínez­Martínez et al., 2006). 
to facilitator of CN–NFAT signaling (Liu et al., 2009; Shin 
et al., 2011). We found that CN activity was not signifi­
cantly affected in VSMCs or aortic tissue from Rcan1/ 
mice. Thus, using the RII phosphopeptide as a specific sub­
strate, CN activity was similar in VSMCs and aortic tissue 
extracts from Rcan1+/+ or Rcan1/ mice. In addition, Rcan1 
deficiency did not affect the basal level of NFAT dephos­
phorylation, its subcellular localization, or its DNA binding 
capacity, or the changes to these parameters induced by 
AngII in VSMCs or aortic tissues. Together, these data indi­
cate that CN does not mediate Rcan1­dependent regulation 
of VSMC migration and pathological vascular remodeling. 
It may thus be that Rcan1 regulates vascular wall remodeling 
through interaction with other proteins. In this regard, 
known RCAN1­interacting proteins relevant to gene activa­
tion include Raf­1 (Cho et al., 2005), 14–3­3 (Abbasi et al., 
2006), and NF­kB–inducing kinase (Lee et al., 2008).
The precise mechanism of neointimal growth in resteno­
sis is not clear. AngII greatly exacerbates neointima growth 
of injured rat arteries (Schwartz et al., 1995; van Kleef et al., 
1996), and a role in AngII­induced remodeling in rat arteries 
was recently reported for Akt (Li et al., 2005). However, 
although the CN–NFAT axis is implicated in neointimal 
growth induced by balloon injury (Satonaka et al., 2004; Liu 
et al., 2005), there have been no studies linking these actions 
of AngII and CN–NFAT signaling. In this study, using a 
femoral artery injury model in mice, we show that CsA inhibits 
not only the vascular remodeling caused by guidewire injury 
but also the sharply exacerbated damage caused by AngII. 
More importantly, our data provide further insight into how 
CN mediates AngII­induced damage. The identification of 
Rcan1-4 as a CN­sensitive AngII­activated gene in VSMCs, 
together with the protection of Rcan1/ mice against 
AngII­induced restenosis, indicates that Rcan1­4 is a key 
mediator of AngII­induced wall remodeling in this model 
of restenosis.
AAA, another example of pathological vascular remodel­
ing, is also potently induced by AngII, although again the 
mechanisms are unclear. A recent study showed that cy­
clophilin A secreted by VSMCs mediates AngII­induced AAA 
formation in Apoe/ mice (Satoh et al., 2009). CsA binds 
cyclophilin A, and it is this complex, not cyclophilin A alone, 
which binds CN and inhibits its activity (Liu et al., 1991). In­
hibition of AAA by CsA could thus involve blockade of 
cyclophilin A secretion, interference in its activity, or inhibi­
tion of CN. However, because the LxVP peptide inhibits CN 
phosphatase activity independently of cyclophilin A, an effect 
of CsA on CN phosphatase activity seems more likely.
Many complex signaling pathways are stimulated after 
binding of AngII to its cell surface receptors. AngII­activated 
pathways include those mediated by diacylglycerol and pro­
tein kinase C; Janus kinase 2 and members of the signal trans­
ducer and activator of transcription family; the Src kinase family 
and its downstream effectors Akt and mitogen­activated pro­
tein kinases; and phospholipases PLD and PLA2, which 
induce the production of reactive oxygen species. In addition, 
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obtained from Sigma­Aldrich. 1 µM calcium ionophore A23187 (Io), 
106M AT1RB (ZD­7155 hydrochloride), and 200 ng/ml CsA were ob­
tained from EMD, Tocris Bioscience, and LD laboratories, respectively. 
Cells were transfected by the Lipofectamine PLUS (Invitrogen) method. VSMCs 
were infected with lentiviruses expressing 3.3 × 108 pfu/ml GFP­peptide 
fusion proteins or adenoviruses expressing either GFP­tagged Rcan1 (Adeno­
Rcan1) or GFP (Adeno­GFP; 1.6 × 108 pfu/ml). Infection efficiency was 
monitored by flow cytometry (FACSCanto; BD).
VSMCs were transfected using Lipofectamine PLUS with a luciferase 
reporter driven by the RCAN1­4­intronic promoter (350/+83 DSCR­
luc; provided by T. Minami, Research Center for Advanced Science and 
Technology, University of Tokyo, Tokyo, Japan) or its mutant version. 
Cells were left to recover in complete medium for 1 d and were then serum 
deprived for 48 h, stimulated for 4 h, and lysed. Luciferase activity was 
detected with the Luciferase Assay System (Promega).
VSMCs in DME containing 0.1% BSA were seeded (5 × 104 per well) 
onto 8­µm pore Transwell 24­well cell culture inserts (Costar). The lower wells 
of the chemotaxis chambers were filled with 1 ml DME (0.1% BSA) containing 
106 M AngII, 106 M AngII plus 200 ng/ml CsA, or 10% FBS. After 4 h, 
nonmigrating cells were removed from the upper filter surfaces, and the filter 
was washed, fixed with 4% paraformaldehyde, and stained with Hoechst. 
Migrated cells were counted on photographs of 10 randomly selected fields on 
the lower surface of the filters. Experiments were performed in duplicate. For 
wound closure assays, Rcan1+/+ or Rcan1/ VSMCs were grown to conflu­
ence in growth medium and then serum deprived for 24 h. A single scrape 
wound was made, and cells were then incubated with or without 106 M 
AngII. Migration into the denuded area was monitored by photomicroscopy.
For immunofluorescence of cultured VSMCs, cells seeded onto cover­
slips were subjected to different treatments, fixed with 3% paraformalde­
hyde, permeabilized with 0.1% Triton­X­100, and then stained with 
anti­NFATc4 (1/1000; Santa Cruz Biotechnology, Inc.), followed by Alexa 
Fluor 488–labeled secondary antibody. As a negative control, species­ and 
isotype­matched IgG were used in place of the primary antibody.
Lentiviral and adenoviral production and infection. Lentiviruses express­
ing GFP­tagged LxVP, LxVPmutant, and VIVIT peptides were obtained by 
transient calcium phosphate transfection of HEK­293 cells, using a three plasmid 
HIV­derived and VSV pseudotyped lentiviral system provided by M.K. Collins 
(University College London, London, England, UK). The supernatant contain­
ing the lentiviral particles was collected 48 h after removal of the calcium phos­
phate precipitate, filtered through a 45­µM PVDF membrane (Steriflip; 
Millipore), and ultracentrifuged for 2 h at 26,000 rpm at 4°C (Ultraclear Tubes, 
SW28 rotor, and Optima l­100 XP Ultracentrifuge; Beckman Coulter). Viruses 
were resuspended in cold sterile DME solution and titrated in Jurkat cells by flow 
cytometry. Infection efficiency (GFP­expressing cells) and cell death (propidium 
iodide staining) were monitored by flow cytometry. Similar infection efficiencies 
with the different constructs were found across experiments.
Adenovirus encoding GFP­tagged Rcan1 (Adeno­Rcan1) and control 
GFP adenovirus (Adeno­GFP) were as previously described (Minami et al., 
2004). Adenovirus infection was performed on 1.6 × 108 pfu/ml of subcon­
fluent primary VSMCs, and expression of the encoded protein was moni­
tored by immunoblotting and flow cytometry.
Histological analysis. Aortas were fixed by perfusing with 4% paraformal­
dehyde. 5­µm paraffin cross sections from fixed aortas were stained with 
hematoxylin­eosin, Masson’s trichrome, or Van Gieson stains or were used for 
immunohistochemistry or immunofluorescence. The following antibodies 
were used for immunohistochemistry or immunofluorescence: anti­Rcan1 
(1/50; Sigma­Aldrich), anti­GFP (1/100; Invitrogen), anti–­SMA (1/300; 
Sigma­Aldrich), anti­CD3 (1/200; Dako), anti­Mac3 (1/200; Santa Cruz 
Biotechnology, Inc.), and anti­vimentin (1/50; Abcam). Sections were 
treated as previously described (Roque et al., 2000). For GFP, CD3, and 
Rcan1 immunohistochemistry, color was developed with diaminobenzi­
dine (DAB; Vector Laboratories), and sections were then counterstained 
with hematoxylin, dehydrated, and mounted in DPX (Fluka). For ­SMA 
The identification of effector molecules downstream from CN 
might facilitate the development of even more selective mole­
cules for use in drug­eluting stents or to prevent AAA expan­
sion. Rcan1­4, which appears to act downstream of CN, might 
be a more promising target than CN. Strategies aimed at 
locally regulating Rcan1­4 function or expression might there­
fore prove to be more specific and less toxic than current 
interventions for inhibiting restenosis and AAA growth.
MATERIALS AND METHODS
Animal experimental design. Animal procedures were approved by the 
CNIC’s Ethics Committee and conformed to European Union guidelines 
for the care and experimental use of animals. Rcan1/ mice were as pre­
viously described (Porta et al., 2007). Double­knockout Apoe/Rcan1/ 
mice were generated by crossing Apoe/ mice (Charles River) with Rcan1/ 
mice. All mice were genotyped by PCR of tail samples using the following 
primers: Rcan1, 5­GGTGGTCCACGTGTGTGAGA­3, 5­ACGTGAA­
CAAAGGCTGGTCCT­3, and 5­ATTCGCAGCGCATCGCCTTC­
TATCGCC­3; and Apoe, 5­TGTCTTCCACTATTGGCTCG­3 and 
5­TGGCGGACCGCTATCAGGAC­3. Control littermates were used 
in all experiments.
2­mo­old mice were administered with various compounds by subcuta­
neous osmotic minipump infusion (Alzet Corp) as described previously 
(Esteban et al., 2004). AngII (Sigma­Aldrich) was administrated at 1 µg/kg/min 
during 28 d in AAA experiments and at 0.5 µg/kg/min during 14 d in femo­
ral artery injury experiments. The AT1R blocker losartan (Fluka) was 
administered at 10 mg/kg/d and the AT2R blocker PD123319 (Sigma­Aldrich) 
at 30 mg/kg/d. Mini pumps loaded with angiotensin receptor blockers or 
CsA (Sandimmun; Novartis; 5 mg/kg/d) were implanted 24 h before 
implantation of mini pumps containing AngII. Control animals were infused 
with saline. Endoluminal injury to the common femoral artery was performed 
by three passages of a 0.25­mm diameter angioplasty guidewire (Advanced 
Cardiovascular Systems) as previously described (Roque et al., 2000). Mini 
pumps for administration of AngII were fitted immediately before injury. 
Stenosis was calculated using the following equation: % stenosis = 100 × 
[Intimal area/(Lumen area + Intimal area)]. Abdominal aortic diameter was 
monitored by high­frequency ultrasound with the VEVO770 system as pre­
viously described (Martin­McNulty et al., 2005). Abdominal aortas with ex­
ternal diameters of ≥1.5 mm were considered to contain an AAA. For jugular 
lentiviral inoculation experiments, animals were inoculated with 100 µl virus 
solution (109 particles/µl in DME/20% FBS) injected directly into the right 
jugular vein 1 mo before mini pump implantation. Infection efficiency was 
monitored by GFP immunohistochemistry.
For bone marrow transplantation, bone marrow–derived cells were ob­
tained from the tibias and femurs of donor Apoe/Rcan1/ or Apoe/ 
Rcan1+/+ mice. Cells (107 in 300 µl PBS) were injected into the tail vein of 
2­mo­old Apoe/Rcan1+/+ recipient mice lethally irradiated with 9 Gy. 
Engraftment success was verified 8 wk after transplantation by PCR analysis 
on blood samples with the same primers used for tail genotyping. AAA was 
then induced by infusion of AngII as described in the previous paragraph.
Cellular procedures. Segments of abdominal and thoracic aortas were dis­
sected from 12­wk­old male C57/BL6 mice or Wistar rats (Charles River). 
Aortas were immersed in PBS, and fat and connective tissue were rapidly re­
moved with fine forceps. The aortas were incubated for 45 min at 37°C in a 
95% air, 5% CO2 atmosphere in serum­free DME (Invitrogen) containing 
2 mg/ml collagenase type 2, l­glutamine, and antibiotics (100 units/ml pen­
icillin and 100 µg/ml streptomycin). Aortas were then cut into small rings, 
and individual explants were seeded in DME containing 10% (rat) or 20% 
(mouse) FBS (Lonza). Explants were not disturbed during the first week. 
After outgrowth of adherent cells, cultures were trypsinized and subcultured. 
All experiments were performed during passages 3–7. Before stimulation, 
cells were rendered quiescent for 48 h by incubation in serum­free medium. 
AngII (106 M), AT2RB (PD123319; 105 M), and 10 ng/ml PMA were 
2136 Rcan1 in vascular wall diseases | Esteban et al.
(1/500 in TBS­T; Porta et al., 2007), mouse monoclonal anti–­tubulin 
(1/40,000; Sigma­Aldrich), and mouse IgG1 polypyrimidine tract­binding 
protein­associated splicing factor (PSF; 1/1,000; Sigma­Aldrich). After 3 × 5 min 
washes in TBS­T, blots were incubated for 1 h at room temperature with 
peroxidase­labeled goat anti–mouse or anti–rabbit IgG (Thermo Fisher Sci­
entific; 1/5,000 in blocking solution). After 3 × 5 min washes in TBS­T and 
one in water, membrane­bound antibody was detected with enhanced che­
miluminescence (ECL) detection reagent (Millipore).
RT and real-time PCR analysis. 2 µg of total RNA was reverse tran­
scribed at 37°C for 50 min in a 20­µl reaction mix containing 200 U 
Moloney murine leukemia virus (MMLV) RT (Invitrogen), 100 ng of ran­
dom primers, and 40 U RNase Inhibitor (Invitrogen). Reactions were ter­
minated by heating to 95°C for 5 min, and samples were stored at 70°C. 
The following PCR primers and TaqMan probes were purchased from 
Applied Biosystems and optimized according to the manufacturer’s protocol: 
18S, rat Rcan1 (Rn00596606_m1), mouse Rcan1 (Mm00627762_m1), 
mouse Tbp (Mm00446973_m1), and mouse Hprt1 (Mm00446968_m1). 
Reactions were incubated in the presence of AmpliTaq Gold DNA poly­
merase (Applied Biosystems) for 2 min at 50°C followed by 10 min at 95°C. 
Reactions were then run over 40 cycles of 95°C for 15 s and 60°C for 1 min. 
18 S rRNA transcripts were detected as an internal control gene for rat sam­
ples, whereas Tbp or Hprt1 were used for mouse samples. Internal controls 
were amplified in the same tube to normalize for variation in input RNA. 
The amount of target mRNA in samples was estimated by the 2CT relative 
quantification method. Ratios were calculated between the amounts of 
mRNA from stimulated and nonstimulated control VSMCs.
Agilent gene expression array assay. Total RNA was isolated from 
VSMCs stimulated with saline, AngII, CsA, or CsA plus AngII. Total RNA 
(n = 4) was processed, and Cy3­labeled cRNA was prepared and hybridized 
for expression analysis to mouse G4122F 4 × 44K Whole Genome arrays 
(Agilent Technologies). Arrays were scanned and analyzed using Feature 
Extraction software v9.5.3.1 (Agilent Technologies) and preprocessed with 
GeneSpring v10 (Agilent Technologies). Raw signal values were thresh­
olded to 1 and arrays were normalized using quantiles (Bolstad et al., 2003). 
Probes with normalized signal values greater than the 20th lower percentile 
were retained if flagged as present or marginal in 75% of the replicates in two 
of the four conditions. Finally, one­way ANOVA was used to identify 
probes that change in at least one condition (P < 0.05), and these probes 
were retained. 1868 probes were used for differential gene expression analy­
sis, which was performed with the limma package from Bioconductor 
(Smyth, 2004). Raw gene expression data are available at http://www.ncbi 
.nlm.nih.gov/projects/geo/ under accession no. GSE31321.
CN phosphatase activity. CN enzyme activity in aortic tissues and VSMC 
extracts was analyzed with the Biomol Green Calcineurin Assay kit (Enzo 
Life Sciences) according to the manufacturer’s instructions.
Statistical analysis. All values are expressed as means ± SEM. Differences were 
evaluated using one­way ANOVA and Bonferroni’s post­hoc test (experiments 
with three or more groups). Statistical significance was assigned at P < 0.05.
Online supplemental material. Fig. S1 shows that AngII induces a sus­
tained activation of the CN–NFAT pathway in VSMCs in vivo. Fig. S2 
shows infection efficiency of VSMCs with lentiviruses expressing GFP fused 
to LxVP, LxVPmut, and VIVIT peptides and illustrates that VIVIT and 
LxVP peptides inhibit AngII­induced VSMC migration. Fig. S3 shows that 
AngII induces Rcan1­4 gene expression and Rcan1­4 promoter activation 
in rat VSMCs. Fig. S4 shows that Rcan1 gene targeting does not alter CN 
activity in VSMCs or aortic tissues. Fig. S5 shows that adenoviral infection 
drives ectopic expression of Rcan1­4 in Rcan1/ VSMCs in vitro. Fig. S6 
illustrates Rcan1 and CD3 expression in sections from injured femoral 
artery. Fig. S7 shows the expression of Rcan1 in SMA­positive cells of 
aneurysmal sections. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20110503/DC1.
immunohistochemistry, color was developed with either DAB or Fast­Red 
Alkaline Phosphatase Substrate Tablets (Sigma­Aldrich). Specificity was tested 
by substitution of primary antibody with nonrelated IgG.
For in situ southwestern histochemistry, 5­µm transverse aorta sections 
were deparaffinized through xylene and alcohols and rehydrated. Sections 
were then fixed with 0.5% paraformaldehyde in PBS for 25 min at 28°C, and 
endogenous alkaline phosphatase was quenched with 5 mM levamisole 
(Sigma­Aldrich). Preparations were then digested with 0.5% pepsin A (Sigma­
Aldrich) in 1 N HCl for 35 min at 37°C and washed twice with HEPES/BSA 
buffer (10 mM HEPES, 40 mM NaCl, 10 mM MgCl2, 1 mM dithiothreitol 
[DTT], 1 mM EDTA, and 0.25% BSA, pH 7.4). Sections were incubated 
with 0.1 mg/ml DNase I in buffer 1 for 30 min at 30°C. Activated NFAT 
proteins were probed with the synthetic sense DNA sequence 5­GATC­
GCCCAAAGAGGAAAATTTGTTTCATACAG­3. This sequence con­
tains a composite site comprising the NFAT and AP1 sites from the mouse 
IL­2 promoter (Jain et al., 1993). The NFAT probe was labeled with digoxi­
genin (Sigma­Aldrich) and diluted to 25 pM in buffer 1 (0.1 M maleic acid 
and 0.15 M NaCl, pH 7.5) containing 0.5 mg/ml poly (dI­dC; Sigma­Aldrich). 
The following negative controls were used: (1) absence of probe; (2) mutant 
NFAT probe (sense 5­GATCGCCCAAAGACCTTAATGGACTTCATA­
CAG­3), (3) NFKB probe (sense 5­GATCAGTTGAGGGGACTTTC­
CCAGGC­3); and (4) competition assay, in which sections were incubated 
with a 200­fold excess of unlabeled NFAT probe before application of the 
labeled probe. After overnight incubation at 37°C in a humidified chamber, 
sections were washed twice with wash buffer (0.03% Tween 20 in buffer 1) 
and were then incubated 1 h in blocking solution (0.1% SSC and 0.1% SDS 
diluted 1:10 in washing buffer). The preparations were washed once more 
with washing buffer and incubated for 2 h at 37°C with an anti­digoxigenin 
antibody conjugated to alkaline phosphatase (1:200 in blocking solution; 
Roche). Next, sections were washed in washing buffer and in buffer 3 (Tris­
HCl 0.1 M, 0.1 M NaCl, and 50 mM MgCl2, pH 9.5) at room temperature. 
Bound alkaline phosphatase was visualized with nitroblue tetrazolium chlo­
ride and 5­bromo­4­chloro­3­indolyl­phosphate (NBT/BCIP; Roche). The 
reaction was stopped by incubation in TE buffer (10 mM Tris and 1 mM 
EDTA, pH 8.0), and sections were dehydrated through a graded ethanol 
series and mounted in 50% glycerol in PBS.
All images except those from immunofluorescence assays were acquired 
at room temperature using a microscope (DM2500; Leica) with 10, 20, or 
40× HCX PL Fluotar objective lenses and acquisition software (Leica Appli­
cation Suite V3.5.0). Images were processed for presentation with Photo­
shop (Adobe) according to the guidelines of this Journal. Immunofluorescence 
images were acquired using an inverted confocal microscope (LSM700; Carl 
Zeiss) with a 40× Plan­Apochromatic oil immersion objective and were 
normalized for each color separately. Presented confocal images are two­ 
dimensional maximal projections of a z­series through the cell depth. Images 
were processed for presentation with Zen 2009 Light Edition (Carl Zeiss) 
and Photoshop according to the guidelines of this Journal.
Immunoblot analysis. After stimulation, cells were washed with ice­cold 
PBS and lysed with 20 mM Hepes, pH 7.6, containing 0.4 M NaCl, 1 mM 
EDTA, 3 mM EGTA, 1 µM dithiothreitol, 1 mM phenylmethylsulfonyl 
fluoride, 100 µM benzamidine, 1 µg/ml pepstatin, 1 µg/ml aprotinin, and 1% 
Triton X­100. Lysates were incubated on a rocking platform for 15 min at 
4°C and centrifuged at 14,000 g (15 min, 4°C). Supernatants were then col­
lected, 2× Laemmli buffer was added, and extracts were boiled for 10 min. 
Proteins were separated under reducing conditions on SDS­polyacrylamide 
gels (6% for NFAT or 12% for RCAN) and transferred to nitrocellulose 
membranes. Membranes were blocked with 5% skim milk (wt/vol) in TBS 
for 1 h at room temperature, washed several times with TBS­T (0.1% Tween­20 
in PBS), and incubated overnight at 4°C in blocking buffer containing the 
appropriate primary antibody. Antibodies and dilutions were as follows: mouse 
monoclonal anti­NFATc1 (1/1,000; Enzo Life Sciences), mouse monoclonal 
anti­NFATc2 (1/1,000; Abcam), rabbit polyclonal anti­NFATc3 (1/1,000; 
Santa Cruz Biotechnology, Inc.), rabbit polyclonal anti­NFATc4 (1/1,000; 
Santa Cruz Biotechnology, Inc.), rabbit polyclonal anti­RCAN1 serum 
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